PIRS [NASD]
Pieris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own9.90% Shs Outstand74.12M Perf Week-12.29%
Market Cap116.10M Forward P/E- EPS next Y-0.60 Insider Trans0.08% Shs Float67.07M Perf Month-16.49%
Income-41.50M PEG- EPS next Q-0.16 Inst Own59.90% Short Float1.82% Perf Quarter-5.99%
Sales27.20M P/S4.27 EPS this Y-3.70% Inst Trans3.24% Short Ratio4.28 Perf Half Y-55.27%
Book/sh0.60 P/B2.62 EPS next Y-7.30% ROA-29.20% Target Price7.00 Perf Year-59.11%
Cash/sh1.10 P/C1.43 EPS next 5Y- ROE-82.00% 52W Range1.51 - 6.15 Perf YTD-58.47%
Dividend- P/FCF- EPS past 5Y-5.30% ROI-94.80% 52W High-72.76% Beta1.01
Dividend %- Quick Ratio2.60 Sales past 5Y40.10% Gross Margin- 52W Low10.65% ATR0.10
Employees124 Current Ratio2.60 Sales Q/Q12.10% Oper. Margin- RSI (14)43.23 Volatility7.41% 5.87%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume0.74 Prev Close1.57
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume286.16K Price1.67
Recom1.00 SMA20-5.10% SMA50-8.16% SMA200-41.45% Volume94,780 Change6.69%
Mar-13-20Upgrade Robert W. Baird Neutral → Outperform $5
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Jul-22-15Initiated ROTH Capital Buy $7
Aug-10-22 06:20AM  
Aug-04-22 02:03PM  
09:35AM  
07:00AM  
Jul-28-22 07:20AM  
Jul-14-22 06:29AM  
Jun-02-22 08:00AM  
May-18-22 09:35AM  
08:00AM  
May-16-22 09:35AM  
08:29AM  
May-11-22 08:45AM  
07:00AM  
May-04-22 08:00AM  
Apr-15-22 11:00AM  
Apr-09-22 06:00AM  
Apr-08-22 06:15AM  
Apr-05-22 12:00PM  
Mar-04-22 04:00PM  
Mar-01-22 11:05AM  
07:00AM  
Feb-28-22 09:25AM  
Feb-23-22 08:00AM  
Feb-04-22 08:58AM  
Jan-28-22 08:00AM  
Jan-27-22 06:23PM  
Jan-16-22 10:30AM  
Jan-14-22 08:00AM  
Jan-03-22 07:00AM  
Dec-15-21 12:53PM  
Dec-06-21 09:33AM  
Nov-11-21 08:05AM  
Nov-08-21 08:00AM  
Nov-02-21 09:05AM  
07:00AM  
Oct-26-21 08:00AM  
Oct-14-21 10:00AM  
Oct-06-21 08:00AM  
Sep-09-21 08:00AM  
Sep-08-21 10:31AM  
Aug-27-21 10:40AM  
Aug-24-21 09:00AM  
Aug-06-21 09:42AM  
Aug-04-21 09:25AM  
07:00AM  
Aug-03-21 08:00AM  
Jul-28-21 08:00AM  
Jun-30-21 08:31AM  
Jun-25-21 09:24AM  
07:00AM  
06:18AM  
05:23AM  
Jun-24-21 10:03AM  
08:00AM  
Jun-19-21 05:34AM  
May-26-21 06:37PM  
08:32AM  
May-25-21 01:32PM  
11:06AM  
09:07AM  
08:00AM  
May-20-21 08:00AM  
May-19-21 05:41AM  
May-17-21 08:50AM  
07:00AM  
06:15AM  
May-10-21 08:00AM  
Apr-26-21 08:00AM  
Apr-10-21 02:15PM  
Mar-30-21 09:45AM  
07:00AM  
06:15AM  
Mar-29-21 10:05AM  
Mar-25-21 08:17AM  
08:00AM  
Mar-23-21 08:00AM  
Mar-05-21 12:30PM  
Feb-23-21 08:00AM  
Feb-19-21 05:37AM  
Jan-19-21 08:00AM  
Dec-21-20 06:35AM  
Dec-15-20 08:39PM  
Nov-24-20 02:29PM  
Nov-10-20 08:00AM  
Nov-06-20 09:26AM  
Nov-04-20 09:05AM  
07:58AM  
07:00AM  
06:15AM  
Oct-28-20 08:00AM  
Oct-05-20 11:40AM  
Sep-28-20 12:50PM  
Sep-20-20 11:00AM  
Sep-03-20 04:30PM  
Aug-12-20 12:45PM  
12:41PM  
Aug-10-20 08:10AM  
07:00AM  
06:30AM  
Aug-04-20 11:13AM  
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demuth TimChief Medical OfficerMay 13Buy1.716,00010,2606,000May 16 08:19 PM
Olwill ShaneChief Development OfficerAug 30Option Exercise1.5238,40058,36843,038Sep 01 04:38 PM
Olwill ShaneChief Development OfficerAug 30Sale5.1138,400196,3804,638Sep 01 04:38 PM